X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (25191) 25191
Newspaper Article (302) 302
Newsletter (209) 209
Book Chapter (176) 176
Magazine Article (40) 40
Transcript (19) 19
Book / eBook (3) 3
Reference (3) 3
Web Resource (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21871) 21871
female (10938) 10938
male (8772) 8772
middle aged (7736) 7736
antibodies, monoclonal, humanized (7085) 7085
antibodies, monoclonal - therapeutic use (6924) 6924
adult (6412) 6412
oncology (6194) 6194
aged (5946) 5946
treatment outcome (5704) 5704
antibodies, monoclonal - adverse effects (5384) 5384
antibodies, monoclonal, humanized - therapeutic use (5237) 5237
antibodies, monoclonal, humanized - adverse effects (4596) 4596
monoclonal antibodies (4298) 4298
bevacizumab (4013) 4013
animals (3865) 3865
cancer (3679) 3679
care and treatment (3470) 3470
therapy (3290) 3290
antibodies, monoclonal - administration & dosage (3197) 3197
antibodies, monoclonal, humanized - administration & dosage (3157) 3157
chemotherapy (3024) 3024
pharmacology & pharmacy (2988) 2988
drug therapy (2795) 2795
immunology (2753) 2753
monoclonal-antibody (2690) 2690
antineoplastic combined chemotherapy protocols - therapeutic use (2640) 2640
antineoplastic agents - therapeutic use (2465) 2465
immunotherapy (2459) 2459
medicine & public health (2434) 2434
clinical trials (2422) 2422
double-blind (2340) 2340
research (2332) 2332
safety (2229) 2229
aged, 80 and over (2189) 2189
antibodies (2098) 2098
health aspects (2076) 2076
adalimumab (2022) 2022
efficacy (1868) 1868
antineoplastic agents - adverse effects (1863) 1863
trastuzumab (1780) 1780
patients (1758) 1758
infliximab (1721) 1721
antineoplastic combined chemotherapy protocols - adverse effects (1705) 1705
retrospective studies (1686) 1686
breast neoplasms - drug therapy (1662) 1662
hematology (1658) 1658
clinical trials as topic (1596) 1596
analysis (1589) 1589
tumor necrosis factor-alpha - antagonists & inhibitors (1557) 1557
rheumatology (1554) 1554
abridged index medicus (1552) 1552
ophthalmology (1517) 1517
risk factors (1517) 1517
angiogenesis inhibitors - therapeutic use (1494) 1494
metastasis (1407) 1407
young adult (1404) 1404
tumors (1365) 1365
cetuximab (1363) 1363
vascular endothelial growth factor a - antagonists & inhibitors (1358) 1358
adolescent (1354) 1354
angiogenesis inhibitors - adverse effects (1342) 1342
follow-up studies (1342) 1342
trial (1322) 1322
breast cancer (1314) 1314
rituximab (1282) 1282
review (1275) 1275
arthritis, rheumatoid - drug therapy (1269) 1269
immunosuppressive agents - therapeutic use (1269) 1269
disease-free survival (1264) 1264
endothelial growth-factor (1255) 1255
medicine, research & experimental (1253) 1253
medicine, general & internal (1248) 1248
rheumatoid arthritis (1229) 1229
mice (1222) 1222
internal medicine (1215) 1215
antibodies, monoclonal - pharmacology (1210) 1210
medical research (1164) 1164
transplantation (1164) 1164
surgery (1143) 1143
disease (1137) 1137
expression (1135) 1135
dermatology (1132) 1132
drug administration schedule (1117) 1117
hematology, oncology and palliative medicine (1103) 1103
rheumatoid-arthritis (1093) 1093
drug therapy, combination (1087) 1087
etanercept (1086) 1086
angiogenesis inhibitors - administration & dosage (1074) 1074
dose-response relationship, drug (1073) 1073
cytokines (1069) 1069
time factors (1063) 1063
antibody (1057) 1057
randomized controlled trials as topic (1051) 1051
studies (1049) 1049
proteins (1033) 1033
antirheumatic agents - therapeutic use (1028) 1028
vascular endothelial growth factor (1023) 1023
prospective studies (1011) 1011
severity of illness index (996) 996
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (25183) 25183
Japanese (235) 235
German (233) 233
French (224) 224
Spanish (118) 118
Chinese (51) 51
Italian (43) 43
Portuguese (36) 36
Hungarian (20) 20
Polish (20) 20
Russian (20) 20
Dutch (16) 16
Danish (14) 14
Norwegian (7) 7
Swedish (7) 7
Czech (6) 6
Finnish (4) 4
Hebrew (3) 3
Korean (3) 3
Arabic (2) 2
Romanian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 8, pp. 711 - 721
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 374, Issue 21, pp. 2044 - 2053
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2016, Volume 139, Issue 2, pp. AB37 - AB37
...Rationale Humanized monoclonal antibodies (MoAbs) represent a new relevant and increasing therapy. The need to change the MoAb because of adverse reactions (AR... 
Allergy and Immunology | Antigen-antibody reactions | Monoclonal antibodies | Complications and side effects
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 17, pp. 1609 - 1618
... and overall survival, with an increase in some side effects. 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INFUSIONAL FLUOROURACIL | LEUCOVORIN | MANAGEMENT | PHASE-III | GUIDELINES | IRINOTECAN | OXALIPLATIN | CHEMOTHERAPY | FOLFIRI | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Clinical cancer research, ISSN 1557-3265, 2017, Volume 23, Issue 21, pp. 6441 - 6449
Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy... 
INTERLEUKIN-2 | MELANOMA | SOLID TUMORS | REFRACTORY NEUROBLASTOMA | ONCOLOGY | PHASE-I TRIAL | CYCLOPHOSPHAMIDE | IMMUNOTHERAPY | RECURRENT | CELLULAR CYTOTOXICITY | PLUS | Drug-Related Side Effects and Adverse Reactions - blood | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Neuroblastoma - blood | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Infant | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Dacarbazine - analogs & derivatives | Killer Cells, Natural - immunology | Camptothecin - administration & dosage | Female | Child | Neoplasm Recurrence, Local - blood | Neuroblastoma - pathology | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Dacarbazine - administration & dosage | Gangliosides - antagonists & inhibitors | Interleukin-2 Receptor alpha Subunit - blood | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Cell- and Tissue-Based Therapy | Gangliosides - immunology | Disease-Free Survival | Ifosfamide - administration & dosage | Neuroblastoma - drug therapy | Adolescent | Topotecan - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Interleukin-2 - blood | Toxicity | Cytotoxicity | Malignancy | Neuroblastoma | Cerebrospinal fluid | Pain | Interleukin 2 | Surgery | Myelosuppression | Children | Natural killer cells | Antibody-dependent cell-mediated cytotoxicity | Thrombocytopenia | Immune response | Cytokines | Ifosfamide | Granulocyte-macrophage colony-stimulating factor | Hypersensitivity | Etoposide | Pharmacology | Patients | Irinotecan | Cyclophosphamide | Chemotherapy | Experimental design | Monoclonal antibodies | Carboplatin | Temozolomide | Pharmacokinetics | Cancer | Index Medicus
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 2018, Volume 84, Issue 6, pp. 1238 - 1249
Journal Article
British journal of dermatology (1951), ISSN 0007-0963, 10/2015, Volume 173, Issue 4, pp. 930 - 939
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 361, Issue 8, pp. 745 - 755
.... This placebo-controlled study investigated the effects of denosumab, a fully human monoclonal antibody against the receptor activator of nuclear factor-κ... 
ZOLEDRONIC ACID | FRACTURE | MEDICINE, GENERAL & INTERNAL | PLACEBO | BONE-MINERAL DENSITY | RISK | COMPLICATIONS | RANDOMIZED CONTROLLED-TRIAL | POSTMENOPAUSAL WOMEN | OSTEOPOROSIS | ALENDRONATE | Lumbar Vertebrae - injuries | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Male | Osteoporosis - drug therapy | Prostatic Neoplasms - physiopathology | Bone Remodeling - drug effects | Incidence | Antibodies, Monoclonal, Humanized | Spinal Fractures - prevention & control | RANK Ligand - pharmacology | Injections, Subcutaneous | Aged, 80 and over | RANK Ligand - therapeutic use | Gonadotropin-Releasing Hormone - agonists | Lumbar Vertebrae - physiology | Prostatic Neoplasms - drug therapy | RANK Ligand - adverse effects | Osteoporosis - chemically induced | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Prostatic Neoplasms - surgery | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Lumbar Vertebrae - drug effects | Denosumab | Bone Density Conservation Agents - pharmacology | Orchiectomy | Bone Density - drug effects | Androgen Antagonists - therapeutic use | Aged | Androgen Antagonists - adverse effects | Fractures, Bone - prevention & control | Osteoporosis | Bone density | Prostate cancer | Older people | Men | Index Medicus | Abridged Index Medicus
Journal Article